%0 Journal Article
%A Fortner, Renée T
%A Schock, Helena
%A Le Cornet, Charlotte
%A Hüsing, Anika
%A Vitonis, Allison F
%A Johnson, Theron S
%A Fichorova, Raina N
%A Fashemi, Titilayo
%A Yamamoto, Hidemi S
%A Tjønneland, Anne
%A Hansen, Louise
%A Overvad, Kim
%A Boutron-Ruault, Marie-Christine
%A Kvaskoff, Marina
%A Severi, Gianluca
%A Boeing, Heiner
%A Trichopoulou, Antonia
%A Papatesta, Eleni-Maria
%A La Vecchia, Carlo
%A Palli, Domenico
%A Sieri, Sabina
%A Tumino, Rosario
%A Sacerdote, Carlotta
%A Mattiello, Amalia
%A Onland-Moret, N Charlotte
%A Peeters, Petra H
%A Bueno-de-Mesquita, H B As
%A Weiderpass, Elisabete
%A Quirós, J Ramón
%A Duell, Eric J
%A Sanchez-Perez, Maria-Jose
%A Navarro, Carmen
%A Ardanaz, Eva
%A Larrañaga, Nerea
%A Nodin, Björn
%A Jirström, Karin
%A Idahl, Annika
%A Lundin, Eva
%A Khaw, Kay-Tee
%A Travis, Ruth C
%A Gunter, Marc
%A Johansson, Mattias
%A Dossus, Laure
%A Merritt, Melissa A
%A Riboli, Elio
%A Terry, Kathryn L
%A Cramer, Daniel W
%A Kaaks, Rudolf
%T Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
%D 2017
%U http://hdl.handle.net/10668/11826
%X CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed
%K CA125
%K MUC16
%K anti-CA125 antibodies
%K autoantibodies
%K early detection markers
%K ovarian cancer
%~